Agios Pharmaceuticals (AGIO) just packed several developments into one stretch. Record third quarter revenue from mitapivat in thalassemia, a longer FDA review for sickle cell disease, and a deep R&D ...
Source LinkAgios Pharmaceuticals (AGIO) just packed several developments into one stretch. Record third quarter revenue from mitapivat in thalassemia, a longer FDA review for sickle cell disease, and a deep R&D ...
Source Link
Comments